Digitalization has become an integral part of medicine, including rheumatology, and not just since the COVID pandemic, whereby this certainly contributed to the acceleration of the development. In the same spirit, the technical capabilities are improving rapidly. Despite this development, the value of the new opportunities, applications, and imaging modalities in daily clinical practice is still comparatively little known. In addition, there are new legal developments that now even allow reimbursement of certified applications from payers in some European countries, so that the number of applications has increased massively in recent months and years. In addition, digital processes and even artificial intelligence have found their way into research and are already part of numerous basic science projects and clinical studies today.
The aim is to publish current work from the field of rheumatology that deals with the opportunities but also the challenges of digitization and imaging in rheumatic diseases. It should include basic scientific topics as well as results of clinical studies with respect to digitization. The focus will be on new findings that relate specifically to rheumatological aspects.
Welcome subjects include the following:
• Digital applications for rheumatic diseases
• Digital disease detection and monitoring
• Wearables
• Remote care solutions
• Digital therapies
• Artificial intelligence (imaging, prediction, treatment)
• Patient/public involvement
Topic Editor PS received financial support from DFG, BMBF, AMGEN, AbbVie, BMS, Celgene, Chugai, Deutscher Psoriasis-Bund, Janssen-Cilag, Lilly, Novartis, Roche, and UCB . Topic Editor VSS received financial support from Novartis, Hexal, Lilly, Roche, and Celgene.
None of the above Research Grants are ongoing.
Digitalization has become an integral part of medicine, including rheumatology, and not just since the COVID pandemic, whereby this certainly contributed to the acceleration of the development. In the same spirit, the technical capabilities are improving rapidly. Despite this development, the value of the new opportunities, applications, and imaging modalities in daily clinical practice is still comparatively little known. In addition, there are new legal developments that now even allow reimbursement of certified applications from payers in some European countries, so that the number of applications has increased massively in recent months and years. In addition, digital processes and even artificial intelligence have found their way into research and are already part of numerous basic science projects and clinical studies today.
The aim is to publish current work from the field of rheumatology that deals with the opportunities but also the challenges of digitization and imaging in rheumatic diseases. It should include basic scientific topics as well as results of clinical studies with respect to digitization. The focus will be on new findings that relate specifically to rheumatological aspects.
Welcome subjects include the following:
• Digital applications for rheumatic diseases
• Digital disease detection and monitoring
• Wearables
• Remote care solutions
• Digital therapies
• Artificial intelligence (imaging, prediction, treatment)
• Patient/public involvement
Topic Editor PS received financial support from DFG, BMBF, AMGEN, AbbVie, BMS, Celgene, Chugai, Deutscher Psoriasis-Bund, Janssen-Cilag, Lilly, Novartis, Roche, and UCB . Topic Editor VSS received financial support from Novartis, Hexal, Lilly, Roche, and Celgene.
None of the above Research Grants are ongoing.
